|
|
Article: CyDex Pharmaceuticals Presents Phase 2 Clinical Trial Results for Captisol-Enabled[R] Budesonide/Azelastine Combination Solution Nasal Spray at American Academy of Allergy Asthma and Immunology AAAAI Meeting.(Clinical report)
- Article from:
- Clinical Trials Week
- Article date:
- March 30, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CyDex Pharmaceuticals, Inc. announced the presentation of Phase 2 clinical trial results of its novel, proprietary Captisol-Enabled[R] budesonide/azelastine nasal spray (CDX-313) for seasonal allergic rhinitis (SAR). The budesonide/azelastine combination nasal spray demonstrated statistically significant improved results over a nasal spray placebo (see also CyDex Pharmaceuticals, Inc.).
A randomized, double-blind, placebo-controlled, three-way cross-over study was conducted in 108 SAR patients to compare the relative efficacy of Captisol-Enabled Budesonide + Azelastine Nasal Spray (Single Solution) and Rhinocort Aqua[R]/ (Suspension) + Astelin[R] Nasal Spray ...